Résumé
‘Liquid biopsy’ was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) in the blood of cancer patients and has been now extended to the analysis of circulating tumor-derived factors, in particular, cell-free tumor DNA (ctDNA), as well as extracellular vesicles (EVs), cell-free microRNAs (cfmiRNAs), mRNA, long noncoding RNA, small RNA, circulating cell-free proteins, and tumor-educated platelets (TEPs). Liquid biopsy is a minimally invasive procedure usually based on sampling of blood, but also of cerebrospinal fluid, urine, sputum, ascites, and theoretically any other body fluid [...].